A new personalized vaccine has been tried out. It is built from a patient's immune cells and tumour cells. In the study the approach has been tried with 25 patients with an advanced form of ovarian cancer; in half of the patients, there was after the vaccination a big increase of T-cells and all those patients survived for a 2-year period compared to only 25% for the others.